Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Acute Biphenotypic Leukemia
Acute Erythroid Leukemia in Remission
Acute Leukemia in Remission
Acute Megakaryoblastic Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia With FLT3/ITD Mutation
Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
Acute Myeloid Leukemia With Inv(3)(q21q26.2); RPN1-EVI1
Acute Myeloid Leukemia With Multilineage Dysplasia
Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214
Acute Undifferentiated Leukemia
Adult Acute Lymphoblastic Leukemia in Complete Remission
B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)
B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1
Childhood Acute Lymphoblastic Leukemia in Complete Remission
DS Stage II Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma
Recurrent Anaplastic Large Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Follicular Lymphoma
Recurrent Hodgkin Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma
Secondary Acute Myeloid Leukemia
T Lymphoblastic Lymphoma
Drug: Fludarabine Phosphate
Procedure: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source|
- Cumulative incidence of non-relapse mortality, defined as death without evidence of disease progression [ Time Frame: Up to 1 year ]
- Incidence of chronic GVHD [ Time Frame: Up to 1 year post-transplant ]Scored according to the National Cancer Institute criteria. The time to onset of limited and extensive chronic GVHD will be recorded.
- Incidence of grades III/IV acute GVHD [ Time Frame: At day 84 ]Grading determined by organ system stages. Grade III/IV acute GVHD is defined as skin: stage IV, liver: stages II-IV, and/or gastrointestinal tract: stages II-IV.
- Relapse of malignancy after transplantation [ Time Frame: Up to 7 years ]Defined by either morphological or cytogenetic evidence of acute leukemia consistent with pre-transplant features, or radiologic evidence of lymphoma progression. When in doubt, the diagnosis of recurrent or progressive lymphoma should be documented by tissue biopsy.
- Donor cell engraftment [ Time Frame: Up to day 84 post-transplant ]Donor chimerism in the T-cell (CD3-positive) and granulocyte (CD33-positive) fractions of sorted peripheral blood greater or equal to 50%.
- Infections [ Time Frame: Up to 7 years ]Reported by anatomic site, date of onset, organism and resolution, if any.
- Neutrophil recovery [ Time Frame: Up to day 84 post-transplant ]Achievement of an ANC greater or equal to 500/mm^3 for three consecutive measurements on different days. The first of the three days will be designated the day of neutrophil recovery.
- Platelet recovery [ Time Frame: Up to day 84 post-transplant ]The first day of a sustained platelet count > 20,000/mm^3 with no platelet transfusions in the preceding seven days.
- Primary graft failure [ Time Frame: At day 84 ]Defined as < 5% donor cluster of differentiation (CD)3 chimerism. Chimerism will be measured by short tandem repeat-polymerase chain reaction on peripheral blood sorted into CD3 and CD33 cell fractions.
- Progression-free survival [ Time Frame: Time interval to relapse/recurrence, to death or to last follow-up, assessed for up to 7 years ]Defined as the minimum time interval to relapse/recurrence, to death or to last follow-up.
- Secondary graft failure [ Time Frame: Up to day 84 post-transplant ]Initial recovery followed by neutropenia with < 5% donor chimerism. If no chimerism assays were performed and ANC is less than 500/mm^3, then it will be counted as a secondary graft failure.
- Toxicity of treatment regimen [ Time Frame: Up to day 90 ]Assessed by Common Terminology Criteria for Adverse Events version 3.0. The incidence of all adverse events greater or equal to grade 3 will be determined.
|Study Start Date:||February 2010|
|Estimated Primary Completion Date:||August 2017 (Final data collection date for primary outcome measure)|
Experimental: Treatment (nonmyeloablative HCT, TBI)
Patients receive fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1. Patients undergo donor peripheral blood stem cell transplant on day 0. Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is >= 1,000/mm^3 for three consecutive days.
Other Names:Biological: Filgrastim
Other Names:Drug: Fludarabine Phosphate
Other Names:Procedure: Laboratory Biomarker Analysis
Correlative studiesDrug: Mycophenolate Mofetil
Other Names:Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Other Names:Procedure: Peripheral Blood Stem Cell Transplantation
Other Names:Drug: Tacrolimus
Given IV or PO
Other Names:Radiation: Total-Body Irradiation
Undergo total-body irradiation (TBI)
I. To demonstrate that use of PBSC in place of marrow as the source of lymphocytes and stem cells for nonmyeloablative transplants from related, haploidentical donors will not result in unacceptable rates of high-grade acute or chronic GVHD, non-relapse mortality or relapse compared to historical data on nonmyeloablative transplants from unrelated donors.
I. Estimates of the rates of neutrophil and platelet recovery, number of red blood cell (RBC) and platelet transfusions, incidences of graft failure, transplant-related toxicities, disease-free survival and overall survival.
Patients receive fludarabine intravenously (IV) over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1. Patients undergo donor peripheral blood stem cell transplant on day 0. Patients then receive tacrolimus IV once daily or orally (PO) twice daily (BID) on days 5-180 (may be continued if active GVHD is present), mycophenolate mofetil IV or PO thrice daily (TID) on days 5-35 (may be continued if GVHD present), and filgrastim IV beginning on day 5 until the absolute neutrophil count (ANC) is >= 1,000/mm^3 for three consecutive days.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01028716
|United States, Washington|
|Fred Hutch/University of Washington Cancer Consortium||Recruiting|
|Seattle, Washington, United States, 98109|
|Contact: Rachel B. Salit 206-667-1317 firstname.lastname@example.org|
|Principal Investigator: Rachel B. Salit|
|Principal Investigator:||Rachel Salit||Fred Hutch/University of Washington Cancer Consortium|